Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats

<table>The six biomarkers that were regulated differently in SFSBP and its constituent groups. (A) sham group, (B) MI group, (C) SFSBP group, (D) ginsenoside Rb1, (E) ginsenoside Re, (F) bufalin, (G) cinnamic acid, (H) muscone, (I) borneol, and (J) cholic acid. *<i>P</i> &lt; 0.05 and **<i>P </i>&lt; 0.01 when compared with MI group; <sup>#</sup><i>P </i>&lt; 0.05, <sup>##</sup><i>P </i>&lt; 0.01 when compared with sham group. The number on the <i>y-axis </i>represents the peak areas of these biomarkers. </table>

Evidence-Based Complementary and Alternative Medicine

fig4

Figure 4

Figure 4: Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats 

Figure 4 | Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats 